Filing summary
Entity and period: The supplied filing is Cara Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2015, signed August 10, 2015. This does not match the request metadata identifying Tvardi Therapeutics, Inc.; verify the issuer before relying on this summary.
Business context and reporting period
Cara was a clinical-stage biopharmaceutical company developing kappa opioid receptor-targeting treatments for pain and pruritus. Its leading programs were intravenous (I.V.) CR845 and Oral CR845. The filing reports the three and six months ended June 30, 2015, compared with the same periods in 2014. The company had no product sales; reported revenue primarily came from collaboration and license arrangements.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0.874 million in 2015; $0.960 million in 2014 | $1.363 million in 2015; $1.138 million in 2014 |
| Operating expenses | $6.606 million in 2015; $4.672 million in 2014 | $11.813 million in 2015; $8.271 million in 2014 |
| Operating loss | $5.732 million in 2015; $3.712 million in 2014 | $10.450 million in 2015; $7.133 million in 2014 |
| Net loss | $5.684 million in 2015; $3.645 million in 2014 | $10.373 million in 2015; $7.028 million in 2014 |
| Basic and diluted loss per share | $0.25 in 2015; $0.16 in 2014 | $0.45 in 2015; $0.37 in 2014 |
At June 30, 2015, cash and cash equivalents were $43.191 million, down from $52.663 million at December 31, 2014. Total assets were $46.441 million; current liabilities were $3.239 million, including $3.150 million of accounts payable and accrued expenses and $0.089 million of deferred revenue. Stockholders’ equity was $42.470 million and accumulated deficit was $90.574 million. The balance sheet reports no debt liability. Six-month operating cash use was $9.495 million, investing cash use was $0.012 million, and financing cash provided was $0.035 million. No operating margin is presented; the company reported operating losses.
Material changes versus prior comparable periods
- Second-quarter revenue decreased 9% year over year, while first-half revenue increased 20%. The first-half increase reflected higher amortization of deferred Maruishi collaboration revenue; there was no license or milestone revenue in 2015, compared with $0.302 million in 2014.
- R&D expense increased 46% in the quarter and 49% for the first half. The company attributed the rise mainly to I.V. CR845 pruritus work, the human abuse liability study, and preparation for planned I.V. and oral trials.
- General and administrative expense rose 31% in the quarter and 30% for the first half, reflecting headcount, compensation, professional and investor-relations costs.
- First-half operating cash use increased from $7.330 million to $9.495 million. The 2014 comparative period included $57.762 million of net IPO proceeds; 2015 financing cash inflow was limited to stock-option exercises.
Outlook, commentary, and risks
- Management expected June 30 cash, together with proceeds from the subsequent offering, to fund operating expenses and capital requirements through the end of 2017, excluding potential collaboration milestones. Before that offering, management said June 30 cash alone was expected to cover more than one year. Both estimates depended on clinical timing and spending assumptions.
- On August 4, 2015, after quarter-end, Cara completed a public offering of 4,327,956 shares, including the underwriters’ fully exercised option, and reported approximately $75.060 million in net proceeds.
- Management expected substantial continuing losses and increasing R&D costs. Planned development included an I.V. CR845 adaptive Phase 3 acute-pain trial anticipated to start in third-quarter 2015, two additional acute-pain Phase 3 trials planned for first-half 2016, and an Oral CR845 Phase 2a osteoarthritis trial planned for third-quarter 2015. These were plans, not assured outcomes.
- In July 2015, Cara reported positive top-line results from its I.V. CR845 Phase 2 uremic-pruritus trial and planned FDA discussions and requests for breakthrough-therapy and orphan-drug designations. The filing cautions that such designations are discretionary and would not assure faster review or approval.
- Key risks include clinical-trial results and timing, regulatory approval, financing needs, commercialization and market acceptance, intellectual-property protection, and reliance on collaborators and third-party manufacturers. Cara stated it would need additional capital beyond anticipated resources for all development objectives, particularly Oral CR845; future financing could dilute shareholders or require unfavorable terms.
- Operating lease commitments totaled $2.098 million. The company reported no material legal proceedings, no material changes to internal controls, and no off-balance-sheet arrangements.
Investor verification priorities
- Confirm that Cara Therapeutics, rather than Tvardi Therapeutics, is the intended issuer and filing.
- Verify receipt and net proceeds of the August 2015 offering, and assess the dilution from the 4.328 million new shares.
- Track actual cash burn against management’s end-of-2017 runway estimate and planned clinical spending.
- Check subsequent FDA feedback, trial initiation and enrollment, and whether the uremic-pruritus designations were requested or granted.
- Assess the durability of collaboration revenue, potential milestone timing, and the company’s need and ability to raise further capital.